Edallia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 19.95%
- Profit Growth 262.81%
- Ebitda 100.63%
- Net Worth 57.72%
- Total Assets -1.59%
About Edallia Pharmaceuticals
Edallia Pharmaceuticals Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 April 2018 (Six years and ten months 4 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shubhangi Parmale and Amol Parmale serve as directors at the Company.
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999PN2018PTC175988
-
Company No.
175988
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Apr 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
What products or services does Edallia Pharmaceuticals Private Limited offer?
Edallia Pharmaceuticals Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Kidney Drugs, Common Disease Medicines, Pharmaceutical Capsules, Pharmaceutical Medicine, Digestive System Drugs & Medicines, Antacid Drugs, Pre & Probiotic Capsule.
Who are the key members and board of directors at Edallia Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shubhangi Parmale
|
Director | 12-Apr-2018 | Current |
|
Amol Parmale
|
Director | 31-Dec-2019 | Current |
Financial Performance of Edallia Pharmaceuticals.
Edallia Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.95% increase. The company also saw a substantial improvement in profitability, with a 262.81% increase in profit. The company's net worth Soared by an impressive increase of 57.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edallia Pharmaceuticals?
Unlock access to Edallia Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Edallia Pharmaceuticals?
Unlock and access historical data on people associated with Edallia Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Edallia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Edallia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
